

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 6, 2026**

**Outlook Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37759**  
(Commission File Number)

**38-3982704**  
(IRS Employer Identification No.)

**111 S. Wood Avenue, Unit #100**  
**Iselin, New Jersey**  
(Address of principal executive offices)

**08830**  
(Zip Code)

Registrant's telephone number, including area code: **(609) 619-3990**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock	OTLK	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 6, 2026, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. The Board has resolved to reduce its size to nine directors immediately upon Dr. Haller’s resignation. Dr. Haller was a Class II director of the Board and served serve as a member of the Nominating and Corporate Governance Committee. A copy of Dr. Haller’s resignation letter is included as Exhibit 99.1 to this Current Report on Form 8-K.

Dr. Haller’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.

The Company and Board thank Dr. Haller for her service and are grateful for her valuable contributions during her tenure.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
<a href="#">99.1</a>	<a href="#">Resignation letter dated March 6, 2026, from Dr. Julia Haller.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Outlook Therapeutics, Inc.**

Date: March 11, 2026

By: /s/ Lawrence A. Kenyon  
Lawrence A. Kenyon  
Chief Financial Officer

---



840 Walnut Street  
Suite 1510  
Philadelphia, PA 19107

**Julia A. Haller, MD**  
**Ophthalmologist-in-Chief and**  
**William Tasman, MD, Endowed Chair**

**Professor and Chair of Ophthalmology**  
Sidney Kimmel Medical College at  
Thomas Jefferson University

Jhaller@willseye.org  
T 215-928-3073

March 6, 2026

Mr. Bob Jahr  
Chief Executive Officer  
Outlook Therapeutics, Inc.  
111S. Wood Ave, Unit #100  
Iselin, NJ 08830

Dear Bob,

It has been a real honor and pleasure to serve on the Board of Directors of Outlook Therapeutics for the last few years.

As you are aware, I have taken on new responsibilities as CEO here at Wills Eye Hospital. As a result, time constraints are forcing me to limit my outside commitments.

To this end, and with regret and respect, I will need to step down from the Outlook Therapeutics board effective March 10, 2026.

I am so appreciative of the opportunity over the last years to work with you and the tremendous team at Outlook to bring new therapies to patients with unmet needs.

I wish the company the very best of luck. You can count on my continued support.

With warmest regards,

A handwritten signature in blue ink that reads "Julia".

Julia A. Haller, MD  
Chief Executive Officer and Ophthalmologist-in-Chief

---